Theraclone Sciences has completed the dosing of the first patient in a randomised, double-blind, dose-escalation Phase I trial to investigate TCN-032 as a treatment for influenza A virus.
The trial is supported in part by Theraclone’s multi-year R&D agreement with Zenyaku Kogyo to identify conserved, essential antibody targets and develop candidates for the treatment of pandemic and severe seasonal influenza.
TCN-032 was discovered using Theraclone’s I-STAR platform.
The Phase I study will enrol up to 40 healthy adult volunteers to assess the safety profile of a single intravenous administration of TCN-032 compared to placebo.
The study will also provide pharmacokinetic and immunogenicity data.
Study results are expected in the first half of 2012 and are required for commencement of proof-of-concept clinical trials.
